Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- TTAN -17.8% (also CRO to step down), CASY -11%, BRZE -10.6%, SAIL -4.4%, SFD -3.5% (guidance)
Other news:
- TYRA -22.5% (posts initial Phase 2 SURF302 data for dabogratinib in LG IR NMIBC)
- PYXS -20.7% (posts updated Phase 1 MICVO data in recurrent/metastatic head and neck cancer)
- EVMN -8.4% (EVO756 misses Phase 2b primary endpoint in atopic dermatitis; will not advance program in AD)
- BKV -6.8% (launches $400 mln convertible senior notes offering due 2031)
- TH -5.7% (prices 14M-share secondary at $18.50; to repurchase about $30 mln of stock)
- IRT -5.7% (Independence Realty Trust and Centerspace (CSR) to merge in $8.1 billion combination)
- INGM -5.6% (prices 13.125M-share secondary at $27.25; authorizes concurrent stock repurchase)
- RZLT -4.1% (FDA still reviewing Phase 3 sunRIZE data for ersodetug in congenital HI)
- LFST -3.9% (launches 22.25 mln-share secondary offering; authorizes concurrent 2.0 mln-share buyback)
- SB -3.8% (contemplating a private placement of approximately 12,000,000 new shares of common stock)
- SNAP -1.6% (names new Chief Commercial Officer)
- BILI -1.5% (confirmed the completion of $500 mln 2031 convertible notes offering; Tencent-related $200 mln note subscription, share repurchase still pending)
- TPG -1.3% (discloses departure of President)
- AHCO -1.3% (names new CFO)